| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2833 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4353 |
| filingDate |
2015-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d7d1faefaa37531d8ab5a07bf48def4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e5758b75a463dff93dcd41336dbc44b |
| publicationDate |
2016-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016054511-A1 |
| titleOfInvention |
Use of mtor inhibitors for prevention of aging-associated dysfunction of stem cells |
| abstract |
Disclosed are methods and compositions for the inhibition of the development of early neoplastic lesions or hyperplastic lesions in the mammary glands or the prevention breast cancer in a patient who has been identified as being at risk for developing breast cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018143826-A1 |
| priorityDate |
2014-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |